Edwards Lifesciences announces approval of new stock repurchase program

By Elaine Rigoli

Tampa, Fla., May 11 - Edwards Lifesciences Corp. announced that its board of directors authorized a new share repurchase program under which the company may repurchase up to four million shares of its outstanding common stock.

The company expects to continue repurchasing shares under its existing two-million share repurchase program, which began in September 2005.

Under that authorization, Edwards has repurchased more than 1.1 million shares for a total of $48.5 million.

Since becoming a publicly traded company in 2000, Edwards' board of directors has authorized five repurchase programs totaling 12 million shares, including the one announced Thursday.

As of April 30, the company had approximately 58.9 million common shares outstanding.

Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular opportunities including heart valve disease, peripheral vascular disease and critical-care technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.